TICKERNERD
Menu
CLDICLDIHealthcare · Biotechnology

CLDI Stock Forecast: Calidi Biotherapeutics, Inc. Price Predictions for 2026-2027

Last close, 4 Sept 2026
$1.39

Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 23 of 100 as at 7 Sept 2026 — in the weakest quartile.

Market cap
$3.6M
Ticker Nerd rank
23 / 100
Median analyst target
—
Analysts covering
—
Revenue$0.0
Operating income−$4.2M
Net income−$4.2M
Free cash flow−$4.4M
Quarterly, 8 quarters to 30 June 2026 · latest quarter's figure shown
Ticker Nerd rank

CLDI stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores Calidi Biotherapeutics, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 7 Sept 2026
23 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Size
98
Accruals
87
Issuance
53
Growth
42
Volatility
33
Revisions
25
Quality
13
Value
11
Momentum
1

Size (98): Smaller than most of the companies we track.

Momentum (1): The shares have been drifting down relative to others.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

CLDI stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on CLDI, reported as data — targets and ratings, the market's view beside the model's.

We don’t hold enough price history for this company yet.

Recent analyst actionsNewest first
DateFirmActionRatingTarget
27 June 2024Ladenburg ThalmannInitiatesBuy—
15 May 2024BairdMaintainsOutperform—
21 Mar 2024BairdMaintainsOutperform—
21 Mar 2024HC Wainwright & Co.MaintainsBuy—
22 Nov 2023HC Wainwright & Co.InitiatesBuy—
9 Oct 2023BairdInitiatesOutperform—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. CLDI appears on the weeks it earns a place.

Free, every Monday. Unsubscribe any time.

Estimates

CLDI analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Fundamentals

Calidi Biotherapeutics, Inc. (CLDI) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
0.8×

Cheaper than 71% of US stocks

Price / sales
—
Price / book
0.9×

Cheaper than 76% of US stocks

EV / EBITDA
−0.1×

Cheaper than 61% of US stocks

Growth & margins
Revenue growth (YoY)
—
Earnings growth (YoY)
—
Gross margin
—
Operating margin
0.0%

Higher than 32% of US stocks

Net margin
0.0%

Higher than 30% of US stocks

Returns & dividend
Return on equity
−672.2%

Higher than 2% of US stocks

Return on assets
−134.8%

Higher than 1% of US stocks

Dividend yield
—

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Key statistics

Calidi Biotherapeutics, Inc. (CLDI) statistics: revenue, profit & scale

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • Calidi Biotherapeutics, Inc. has a market value of $3.6M and an enterprise value of $1.5M.

  • Revenue in the twelve months to 30 June 2026: $0.0.

  • Net income over the same four quarters: −$17.5M.

  • Free cash flow in the twelve months to 30 June 2026: −$17.8M.

  • Shares outstanding: 179,812.

  • Trailing P/E: 0.8×; forward P/E: −1.5× — the forward figure prices analyst consensus estimates, not reported earnings.

  • Calidi Biotherapeutics, Inc. employs 29 people.

Statement figures: company filings via Twelve Data, four quarters to 30 June 2026 · market figures as at 8 Sept 2026

Data provided by Twelve Data

Peers

CLDI vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelBiotechnology
CompanyMarket capTKN rank
CLDICalidi Biotherapeutics, Inc.$3.6M
23
GOVXGeoVax Labs, Inc.$3.6M
39
PPCBPropanc Biopharma, Inc.$3.5M
37
SILOSilo Pharma, Inc.$3.8M
25
ARTLArtelo Biosciences, Inc.$3.3M
17
REVBRevelation Biosciences, Inc.$3.9M
8
SXTP60 Degrees Pharmaceuticals, Inc.$3.2M
32

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own Calidi Biotherapeutics, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest CLDI news & analysis

Calidi Biotherapeutics to Participate in the H.C. Wainwright 28th Annual Global Investment Conference

GlobeNewsWire · 8 Sept 2026neutral

Calidi Biotherapeutics announced it will participate in the H.C. Wainwright 28th Annual Global Investment Conference, held September 14–16, 2026 at the Lotte New York Palace Hotel. The company made the announcement on September 8, 2026.

Why it matters — A CLDI watcher would care because company participation in a prominent investment conference indicates potential opportunities for investor engagement and visibility within the financial community.

Calidi Biotherapeutics Reports Second Quarter 2026 Financial Results and Recent Business Highlights

GlobeNewsWire · 13 Aug 2026positive

Calidi Biotherapeutics announced its second quarter 2026 financial results and recent business highlights. The company reported receiving positive pre-IND feedback from the U.S. FDA for CLD-401, indicating agreement on the current development strategy toward a first-in-human study, targeting first patient dosing in Q1 2027.

Why it matters — This regulatory milestone for CLD-401 advances Calidi's pipeline toward its first-in-human study and provides investors with a clearer timeline for clinical development.

Calidi Biotherapeutics Presents New Data on Cytotoxicity and IL-15 SA Expression in Human and Murine Tumor Cells at the American Association for Cancer Research Drug Discovery and Development Conference

GlobeNewsWire · 27 July 2026positive

Calidi Biotherapeutics presented new data on its CLD-401 program and its in situ T-cell engager program at the American Association for Cancer Research Drug Discovery and Development Conference in Boston on July 23, 2026.

Why it matters — The presentation highlights progress in Calidi's pipeline, specifically the CLD-401 program expected to enter the clinic in the first quarter of 2027.

FAQ

Frequently asked questions about CLDI stock

How does Ticker Nerd's model rank CLDI?

As at 7 Sept 2026, Calidi Biotherapeutics, Inc. ranks 23 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Size (98 of 100).

What is the CLDI stock forecast for 2030?

No analyst covering Calidi Biotherapeutics, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for CLDI are extrapolating price history, which says nothing about the business.

What does Calidi Biotherapeutics, Inc. do?

Calidi Biotherapeutics, Inc. is a clinical-stage biotechnology company focused on developing targeted therapies that deliver genetic medicines to sites of disease.

What is the latest news on CLDI?

The most recent item we track (GlobeNewsWire, 8 Sept 2026): "Calidi Biotherapeutics to Participate in the H.C. Wainwright 28th Annual Global Investment Conference". Calidi Biotherapeutics announced it will participate in the H.C. Wainwright 28th Annual Global Investment Conference, held September 14–16, 2026 at the Lotte New York Palace Hotel. The company made the announcement on September 8, 2026.

Company

About Calidi Biotherapeutics, Inc.

Calidi Biotherapeutics, Inc. is a clinical-stage biotechnology company focused on developing targeted therapies that deliver genetic medicines to sites of disease. The company’s current programs center on stem cell-based and oncolytic virus platforms designed to transport therapeutic payloads directly into tumors while helping protect them from premature immune clearance. Its portfolio includes product candidates for cancers such as high-grade glioma and solid tumors, reflecting a focus on oncology and precision delivery methods. Calidi Biotherapeutics also works across systemic and localized treatment approaches, using proprietary cell-based technologies to support tumor targeting, immune activation, and controlled payload delivery. Headquartered in San Diego, California, Calidi Biotherapeutics plays a role in the broader biopharmaceutical market as a developer of advanced immuno-oncology and gene therapy solutions.

CEO Dr. Eric E. Poma Ph.D. · 29 employees · United States · https://www.calidibio.com